Suppr超能文献

胃轻瘫糖尿病患者单剂量和多剂量服用胃复安后的生物利用度及处置情况。

Bioavailability and disposition of metoclopramide after single- and multiple-dose administration in diabetic patients with gastroparesis.

作者信息

O'Connell M E, Awni W M, Goodman M, Cass O, Melikian A P, Wright G J, Matzke G R

机构信息

Department of Medicine, Hennepin County Medical Center, Minneapolis, MN 55415.

出版信息

J Clin Pharmacol. 1987 Aug;27(8):610-4. doi: 10.1002/j.1552-4604.1987.tb03073.x.

Abstract

The disposition of metoclopramide after acute and chronic administration was determined in four diabetic patients with gastroparesis who had a creatinine clearance of 70.8 +/- 10.7 mL/min (mean +/- SD). Single, 10-mg oral and intravenous doses were administered on days 1 and 2, respectively, followed by 10 mg orally every six hours for three weeks. A second, 10-mg intravenous bolus dose was administered on the last morning of chronic therapy. Metoclopramide concentrations were determined by high performance liquid chromatography. The elimination half-life, steady-state volume of distribution, and total body clearance after the initial intravenous dose were 3.9 +/- 1.2 hr, 2.7 +/- 0.3 L/kg, and 0.57 +/- 0.14 L/hr/kg, respectively. The initial bioavailability was 67.7 +/- 12.6%. After three weeks of chronic therapy, no significant differences in total body clearance (0.72 +/- 0.42 L/hr/kg) or bioavailability (77.5 +/- 16.8%) were observed. Thus the pharmacokinetics and bioavailability of metoclopramide were not altered during chronic therapy in these diabetic patients.

摘要

对4名患有胃轻瘫的糖尿病患者进行了研究,以确定急性和慢性给药后胃复安的处置情况,这些患者的肌酐清除率为70.8±10.7 mL/分钟(平均值±标准差)。分别在第1天和第2天给予单次10毫克口服和静脉注射剂量,随后每6小时口服10毫克,持续3周。在慢性治疗的最后一个上午给予第二次10毫克静脉推注剂量。通过高效液相色谱法测定胃复安浓度。初始静脉给药后的消除半衰期、稳态分布容积和全身清除率分别为3.9±1.2小时、2.7±0.3升/千克和0.57±0.14升/小时/千克。初始生物利用度为67.7±12.6%。慢性治疗3周后,未观察到全身清除率(0.72±0.42升/小时/千克)或生物利用度(77.5±16.8%)有显著差异。因此,在这些糖尿病患者的慢性治疗期间,胃复安的药代动力学和生物利用度未发生改变。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验